FindTrial
Sign In

N803

DRUG6 trials

Sponsors

National Cancer Institute (NCI), Rockefeller University, ImmunityBio, Inc., University of Utah, St. Jude Children's Research Hospital

Conditions

B-cell Non Hodgkin LymphomaHead and Neck CancerHead and Neck NeoplasmsHuman Immunodeficiency VirusMetastatic Prostate CancerNeuroblastoma RecurrentNon Hodgkin's Lymphoma Refractory/RelapsedProstate Cancer

Phase 1

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
CompletedNCT04247282
National Cancer Institute (NCI)Head and Neck Cancer, Head and Neck Neoplasms
Start: 2020-06-09End: 2023-06-12Updated: 2025-07-16
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
CompletedNCT05245292
Rockefeller UniversityHuman Immunodeficiency Virus
Start: 2022-12-07End: 2025-12-31Updated: 2026-03-31
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
RecruitingNCT05618925
ImmunityBio, Inc.Non Hodgkin's Lymphoma Refractory/Relapsed
Start: 2025-08-22End: 2027-03-15Target: 20Updated: 2026-04-01
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
WithdrawnNCT07049432
University of UtahB-cell Non Hodgkin Lymphoma
Start: 2026-02-01End: 2031-12-01Updated: 2026-04-01
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Not yet recruitingNCT07756593
Washington University School of MedicineMetastatic Prostate Cancer, Prostate Cancer
Start: 2026-11-30End: 2031-01-31Target: 30Updated: 2026-08-10

Phase 2

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
RecruitingNCT07085338
St. Jude Children's Research HospitalNeuroblastoma Recurrent
Start: 2025-11-10End: 2029-02-01Target: 54Updated: 2026-08-07

Related Papers

GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy
npj Precision Oncology2026-04-18
Singe agent off-the-shelf CAR-NK (CD-19 t-haNK) cell therapy in combination with rituxumab Results in complete response in participants with waldenstrom's macroglobulinemia
Blood2025-11-03
Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection
The Oncologist2025-03-012 citations
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
592 Updated recurrence free survival for neoadjuvant bintrafusp alfa (BA) for HPV unrelated HNSCC and results from BA plus a multitargeted recombinant adenovirus 5 vaccine for HPV unrelated HNSCC
Regular and Young Investigator Award Abstracts2023-10-31
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
Journal of Clinical Investigation2022-06-2176 citations